| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Pager | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $176.59M | Series D-1 | 6/2/2022 | $3.04M | $262.42M | $0.85 | UndisclosedInvestors | ||||
 | Qventus | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $155.63M | Series D-1 | 1/13/2025 | $35.81M | $400.12M | $7.95 | KKR, Bessemer Venture Partners, Northwestern Medicine, HonorHealth, Allina Health | ||||
 | Santa Ana Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $168.34M | Series B-2 | 6/13/2024 | $62.5M | $264.43M | $1.50 | Versant Ventures, TPG, GV, Access Biotechnology, Andreessen Horowitz, RTW Investments | ||||
 | Solv Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $95.05M | Series C | 9/2/2021 | $45M | $399.84M | $4.36 | Acrew Capital, Corner Ventures, Greylock Partners, Benchmark Capital | ||||
 | Tenvie | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $200M | Series A | 1/8/2025 | $158.05M | $391.74M | $1.00 | ARCH Venture Partners, F-Prime Capital, Mubadala Capital | ||||
 | Timberlyne Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $9.88M | Series A | 1/9/2025 | $9.37M | $137.37M | $3.64 | Abingworth, Bain Capital Life Sciences, Venrock, Boyu Capital, Lilly Asia Ventures, Braidwell, 3H Health Investment | ||||
 | Vedanta Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $126.86M | Series B-1 | 8/6/2026 | $22.57M | $113.87M | $0.17 | AMR Action Fund, BNP Paribas | ||||
 | Verana Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $364.32M | Series B-1 | 12/19/2025 | $59.3M | $294.83M | $3.96 | Undisclosed Investors | ||||
 | Viome | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $190.54M | Series D | 8/19/2024 | $25.44M | $402.5M | $5.00 | Khosla Ventures, Bold Capital, West River Group, Marc Benioff | ||||
 | Vista.ai | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $41.1M | Series B | 1/14/2026 | $4.7M | $393.05M | $1.30 | Cedars Sinai Health System, Intermountain Health, University of Utah, Temple University, Tampa General Hospital, Khosla Ventures, Bold Brain Capital | ||||
 | Alto Neuroscience | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $253.17M | Series C | 11/21/2023 | $50.31M | $235.65M | $4.71 | InVivium Capital, Franklin Templeton, Point72, Eli Lilly and Company, Alexandria Venture Investments, Alpha Wave Ventures, Lightswitch Capital, Alkeon Capital, WhatIf Ventures, Windham Venture Partners | ||||
 | Ampersand Biomedicines | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $109.61M | Series B | 3/19/2025 | $65M | $360.94M | $5.80 | Flagship Pioneering, Eli Lilly & Company | ||||
 | Attralus | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $344M | Series B | 2/6/2024 | $172.6M | $428.81M | $7.76 | Logos Capital, Janus Henderson Investors, Redmile Group, Samsara BioCapital, Sarissa Capital Management, Surveyor Capital, Vivo Capital, venBio Partners, Alpha Wave Ventures, Bristol Myers Squibb | ||||
 | BlueWillow Biologics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $37.19M | Series C | 9/19/2022 | $5.9M | $34.12M | $0.09 | Undisclosed Investors | ||||
 | Boundless Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $756.15M | Series C | 5/16/2023 | $100M | $273.76M | $0.70 | Bayer, RA Capital Management, Sectoral Asset Management, Piper Heartland, Healthcare Capital | ||||
 | Conformal | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $122.03M | Series D | 6/5/2023 | $35M | $288.39M | $5.08 | SPRIG Equity, Fidelity | ||||
 | Diagonal Therapeutics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $253M | Series B | 1/8/2026 | $125M | $447.42M | $2.70 | Sanofi Ventures, Janus Henderson Investors, Deep Track Capital, EcoR1 Capital, Logos Capital, Balyasny Asset Management, Woodline Partners, BVF Partners, Atlas Venture, Lightspeed Venture Partners, RA Capital Management, Frazier Life Sciences, Viking Global Investors, Velosity Capital, Checkpoint Capital, RV Invest, Biovision Ventures | ||||
 | DispatchHealth | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $315.45M | Series A-1 | 4/30/2026 | $61.99M | $444.87M | $63.16 | Undisclosed Investors | ||||
 | Egenesis | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.4B | Series D | 9/4/2024 | $90.96M | $332.59M | $0.20 | Lux Capital, ARCH Venture Partners, Khosla Ventures, Farallon Capital Management, Alta Partners, Fresenius Medical Care Ventures, Leaps by Bayer, DaVita, Eisai Innovation, NATCO Pharmaceuticals, Parkwood Corporation | ||||
 | Evozyne | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $109.19M | Series B | 9/27/2023 | $50M | $288.32M | $15.49 | Fidelity Management & Research Company, OrbiMed, NVentures, Paragon Biosciences, Valor Equity Partners | ||||
 | Genalyte | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $30.23M | Series 1 | 1/30/2026 | $30.23M | $58.16M | $0.38 | Undisclosed Investors | ||||
 | Georgiamune | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $167.69M | Series B-1 | 7/16/2026 | $64.09M | $407.96M | $11.11 | Undisclosed Investors | ||||
 | Healthie | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $39.78M | Series B | 10/15/2024 | $23M | $273.02M | $11.77 | TCV, Birchmere Ventures, Velvet Sea Ventures, Greymatter, Watershed | ||||
 | HealthJoy | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $87.95M | Series D | 10/27/2022 | $35M | $179.66M | $2.70 | Valspring Capital, Endeavour Vision, CIBC Innovation Banking, U.S. Venture Partners, Brandon Cruz, Clint Jones, Health Velocity Capital, Nueterra Capital, EPIC Ventures | ||||